4Fioretto P,Solini A.Antihypertensive treatment and multi-factorial approach for renal protection in diabetes. Journal of the American Society of Nephrology . 2005
4Meisinger C,Doring A,Thorand B,et al.Body fat distribution and risk of type 2 diabetes in the general population:are there differences between men and women? The MONICA/KORA Augsburg cohort study[J].Am J Clin Nutr,2006,84(3):483-489.
6Patti G,Nusca A,Chello M,et al.Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronany intervention[J].Am J Cardiol,2008,101(3):279-285.
7Ichiki T,Takeda K,Tokunou T,et al.Downregulation of angiotensin Ⅱ type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells[J].Arterioscler Thromb Vasc Biol,2001,21(12):1896-1901.
8Chello M,Goffredo C,Patti G,et al.Effects of atorvastatin on arterial endothelial function in coronary bypass surgery[J].Eur J Cardiothorac Surg,2005,28(6):805-810.
9Mason JC,Ahmed Z,Mankoff R,et al.Statin-induced expression of decay-accelerating factor protects vascular endothelial against complement-mediated injury[J].Circ Res,2002,91(8):696-703.
10Bonnet J,Mcpherson R,Tedgni A,et al.Comparative effects of 10-mg versus 80-mg atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease:results of the CAP (Comparative Atorvastatin Pleiotropic effects) study[J].Clin Ther,2008,30(12):2298-2313.
